Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00427544
Other study ID # 3208A1-1000
Secondary ID
Status Completed
Phase Phase 1
First received January 25, 2007
Last updated December 3, 2007
Start date February 2007
Est. completion date August 2007

Study information

Verified date December 2007
Source Wyeth is now a wholly owned subsidiary of Pfizer
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to asess the safety and tolerability of ascending single oral doses of PRA-027 in healthy women of nonchildbearing potential. The secondary purpose is to provide the initial pharmacokinetic (PK) and pharmacodynamic (PD) profile of PRA-027 in healthy women of nonchildbearing potential, and to evaluate the effect of a high-fat meal on the PK and PD of PRA-027 administered to healthy women of nonchildbearing potential.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date August 2007
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 60 Years
Eligibility INCLUSION CRITERIA

- Women of nonchildbearing potential (WONCBP) aged 18 to 60 years. Must have a negative pregnancy test result within 48 hours before administration of test article. Women who are surgically sterile must provide documentation of the procedure by an operative report or ultrasound scan.

- Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight ³50 kg. BMI is calculated by taking the subject's weight, in kilograms, divided by the square of the subject's height, in meters, at screening: BMI=weight (kg)/[height (m)]2

- Healthy as determined by the investigator on the basis of screening evaluations.

EXCLUSION CRITERIA

- Any significant cardiovascular, hepatic, renal, respiratory, gynecologic, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.

- A history of drug abuse within 1 year before study day 1, a history of alcoholism within 1 year before study day 1 or consumption of more than 2 standard units of alcohol per day (a standard unit equals 12 ounces of beer, 1½ ounces of 80-proof alcohol, or 6 ounces of wine). Any positive findings during the urine drug screen for amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, and opiates.

- Use of any investigational or prescription drug within 30 days before test article administration. Consumption of any caffeine-containing products (eg, coffee, tea, chocolate, or soda) or alcoholic beverages within 48 hours before study day 1. Consumption of grapefruit or grapefruit-containing products within 72 hours before study day 1. Use of any over-the-counter drugs, including herbal supplements (except for the occasional use of acetaminophen and vitamins =100% of the recommended daily allowance) within 14 days before study day 1.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
PRA-027


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome of this study is to asess the safety and tolerability of ascending single oral doses of PRA-027 in healthy women of nonchildbearing potential.
See also
  Status Clinical Trial Phase
Completed NCT00891657 - Post Market Study for an Adhesion Barrier Following Laparoscopic Myomectomy N/A
Active, not recruiting NCT03323905 - Single Arm Study Using the Symphony -- MRI Guided Focused Ultrasound System for the Treatment of Leiomyomas N/A
Recruiting NCT06135870 - Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)
Recruiting NCT03143114 - Effect of Myomectomy for Intramural Myoma on Fertility Outcomes in Infertile Women N/A
Not yet recruiting NCT06392997 - Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology
Recruiting NCT06143631 - Prescription of Letrozole for Uterine Myoma Phase 4
Recruiting NCT03784976 - Iyengar Yoga Therapy for Dysmenorrhea and Endometriosis N/A
Completed NCT02166411 - Laparoscopic Myomectomy Using Barbed or Conventional Sutures Phase 2
Completed NCT04736095 - 3 Dimensional Ultrasound in Comparison to Hysteroscopy in Myomas
Recruiting NCT02357563 - Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation Phase 4
Recruiting NCT02361879 - Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Phase 4
Recruiting NCT02361905 - Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas Phase 4
Enrolling by invitation NCT03937401 - Oxytocin in MRI-HIFU Phase 4
Completed NCT00746031 - Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids Phase 4
Recruiting NCT00323999 - Hysteroscopic Monopolar and Bipolar Resection N/A
Terminated NCT02825719 - Ulipristal Use in Chinese Population Phase 4
Not yet recruiting NCT03122782 - Hemostatic Effect of Intrauterine Instillation Of Tranexamic Acid In Hysteroscopic Myomectomy Phase 3